COLL Share Price Performance
US$35.73
4.63 (14.89%)
34.2% undervalued intrinsic discount
US$54.33
Fair Value
Price US$35.73
AnalystConsensusTarget US$54.33
Fair ValueUS$54.33
Share Pricen/a
Seeking Alpha • Aug 01
Collegium Pharmaceutical, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
COLL Community Narratives
AN
Fair Value
·Fair Value US$54.33 34.2% undervalued intrinsic discount
Specialty Pharmaceuticals And Diversified Assets Will Drive Future Success
0users have liked this narrative
1users have commented on this narrative
12users have followed this narrative
Specialty Pharmaceuticals And Diversified Assets Will Drive Future Success
Collegium leans on pain medicines today, but it’s also building a second growth engine in an ADHD treatment and adding new products to spread out risk. The catch is that its biggest pain drugs could face copycat competition and tougher pricing rules, while the company’s growing cost base leaves less room for mistakes.Read more
AN
US$54.33
34.2% undervalued intrinsic discount
Fair Value
Revenue
2.29% p.a.
Profit Margin
28.49%
Future PE
9.62x
Price in 2029
US$66.01
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
COLL: Steady 2026 Guidance And Buyback Capacity Will Support Undervalued Profile
Fair Value: US$54.33 34.2% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Collegium Pharmaceutical, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
- 2.31
- 89.17%
- 9.41%
- 295.9%
About COLL
- Founded
- 2002
- Employees
- 423
- CEO
- WebsiteView website
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
